Impax Laboratories (IPXL) Has More Upside, Piper Jaffray Says; PT Raised

Jefferies analyst David Amsellem boosted his price target on Buy-rated Impax Laboratories (NASDAQ: IPXL) to $35.00 (from $27.00) saying there still room for valuation creation despite strength in the name.

Amsellem said a 10-year discounted cash flow (DCF) analysis suggests that "downside for IPXL should Hayward continue to be an issue is relatively manageable (or put another way, there is considerably more upside potential than downside risk for IPXL despite the strength year-to-date)."

For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.

Shares of Impax Laboratories closed at $29.99 yesterday.

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• DA Davidson Starts Everus (ECG) at Buy